Eli Lilly says Foundayo cut predicted diabetes risk up to 57%

Eli Lilly and Company announced on Thursday results from post-hoc analyses of its ATTAIN-1 Phase 3 trial. The data showed that its once-daily oral drug Foundayo (orforglipron) was associated with significant reductions in the predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight and weight-related medical conditions.

At 72 weeks, participants taking Foundayo at daily doses of 5.5 mg, 9 mg and 17.2 mg showed an estimated 45.0%, 50.0% and 57.0% reduction, respectively, in predicted type 2 diabetes risk versus placebo. Patients taking the highest dose of 17.2 mg also experienced an estimated 18.0% reduction in predicted cardiovascular disease risk compared to placebo.

The ATTAIN-1 trial enrolled 3,127 participants across several countries, including the United States, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan. The broader ATTAIN Phase 3 program for orforglipron enrolled more than 4,500 people across two registration trials. Lilly licensed orforglipron from Chugai Pharmaceutical in 2018.